![Zi Qiang Cheng](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Postes actifs de Zi Qiang Cheng
Sociétés | Poste | Début | Fin |
---|---|---|---|
Zion Pharma Ltd.
![]() Zion Pharma Ltd. Miscellaneous Commercial ServicesCommercial Services Zion Pharma Ltd. is a private, Chinese clinical stage biotech company founded in 2018. The company's research operations are located in mainland China and they have additional research operations elsewhere. The company is based in China and has subsidiaries in the country. The company is focused on developing novel, small molecule, anti-tumoral agents using an innovative drug discovery approach. Zion Pharma is capitalizing on its dmpk expertise to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (atm), kirsten rat sarcoma (kras g12d) and smarca2 (brm). | Directeur Général | 01/01/2018 | - |
Président | 01/01/2018 | - | |
Fondateur | 01/01/2018 | - |
Historique de carrière de Zi Qiang Cheng
Statistiques
Internationale
Chine | 2 |
Opérationnelle
Chief Executive Officer | 1 |
Chairman | 1 |
Founder | 1 |
Sectorielle
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Zion Pharma Ltd.
![]() Zion Pharma Ltd. Miscellaneous Commercial ServicesCommercial Services Zion Pharma Ltd. is a private, Chinese clinical stage biotech company founded in 2018. The company's research operations are located in mainland China and they have additional research operations elsewhere. The company is based in China and has subsidiaries in the country. The company is focused on developing novel, small molecule, anti-tumoral agents using an innovative drug discovery approach. Zion Pharma is capitalizing on its dmpk expertise to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (atm), kirsten rat sarcoma (kras g12d) and smarca2 (brm). | Commercial Services |
- Bourse
- Insiders
- Zi Qiang Cheng
- Expérience